News + Filings Transactions
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
|
|
Ros Matthew
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/03/2023 |
4
| Ros Matthew (Director) has filed a Form 4 on Cogent Biosciences, Inc.|
Txns:
| Granted 2,170 options to buy
@ $9.55, valued at
$20.7k
|
|
| 07/05/2023 |
4
| Ros Matthew (Director) has filed a Form 4 on Cogent Biosciences, Inc.|
Txns:
| Granted 1,743 options to buy
@ $11.96, valued at
$20.8k
|
|
| 06/08/2023 |
4
| Ros Matthew (Director) has filed a Form 4 on Cogent Biosciences, Inc.|
Txns:
| Granted 36,700 options to buy
@ $11.7, valued at
$429.4k
|
|
| 04/04/2023 |
4
| Ros Matthew (Director) has filed a Form 4 on Cogent Biosciences, Inc.|
Txns:
| Granted 1,900 options to buy
@ $10.75, valued at
$20.4k
|
|
| 01/04/2023 |
4
| Ros Matthew (Director) has filed a Form 4 on Cogent Biosciences, Inc.|
Txns:
| Granted 1,792 options to buy
@ $11.07, valued at
$19.8k
|
|
| 10/04/2022 |
4
| Ros Matthew (Director) has filed a Form 4 on Cogent Biosciences, Inc.|
Txns:
| Granted 1,419 options to buy
@ $14.33, valued at
$20.3k
|
|
| 07/05/2022 |
4
| Ros Matthew (Director) has filed a Form 4 on Cogent Biosciences, Inc.|
Txns:
| Granted 2,194 options to buy
@ $9.39, valued at
$20.6k
|
|
| 06/09/2022 |
4
| Ros Matthew (Director) has filed a Form 4 on Cogent Biosciences, Inc.|
Txns:
| Granted 30,700 options to buy
@ $4.59, valued at
$140.9k
|
|
| 04/05/2022 |
4
| Ros Matthew (Director) has filed a Form 4 on Cogent Biosciences, Inc.|
Txns:
| Granted 2,650 options to buy
@ $7.92, valued at
$21k
|
|
| 01/04/2022 |
4
| Ros Matthew (Director) has filed a Form 4 on Cogent Biosciences, Inc.|
Txns:
| Granted 2,256 options to buy
@ $8.7, valued at
$19.6k
|
|
| 10/05/2021 |
4
| Ros Matthew (Director) has filed a Form 4 on Cogent Biosciences, Inc.|
Txns:
| Granted 2,463 options to buy
@ $8.54, valued at
$21k
|
|
| 08/18/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/06/2021 |
4
| Ros Matthew (Director) has filed a Form 4 on Cogent Biosciences, Inc.|
Txns:
| Granted 2,225 options to buy
@ $8.02, valued at
$17.8k
|
|
| 04/05/2021 |
4
| Ros Matthew (Director) has filed a Form 4 on Cogent Biosciences, Inc.|
Txns:
| Granted 2,068 options to buy
@ $9.08, valued at
$18.8k
|
|
| 03/15/2021 |
4
| Ros Matthew (Director) has filed a Form 4 on Cogent Biosciences, Inc.|
Txns:
| Granted 60,000 options to buy
@ $8.45, valued at
$507k
|
|
| 02/05/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/02/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/27/2021 |
4
| Ros Matthew (See Remarks) has filed a Form 4 on Epizyme, Inc.|
Txns:
| Sold 2,872 shares
@ $11.41, valued at
$32.8k
|
|
| 01/06/2021 |
4
| Ros Matthew (Director) has filed a Form 4 on Cogent Biosciences, Inc.|
Txns:
| Granted 1,641 options to buy
@ $7.6191, valued at
$12.5k
|
|
| 10/02/2020 |
4
| Ros Matthew (Director) has filed a Form 4 on Unum Therapeutics Inc.|
Txns:
| Granted 9,247 options to buy
@ $2.26, valued at
$20.9k
|
|
| 07/06/2020 |
4
| Ros Matthew (Director) has filed a Form 4 on Unum Therapeutics Inc.|
Txns:
| Granted 35,280 options to buy
@ $0.47, valued at
$16.6k
|
|
| 06/30/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/30/2020 |
4/A
| Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] |
| 06/22/2020 |
4
| Ros Matthew (See Remarks) has filed a Form 4 on Epizyme, Inc.|
Txns:
| Sold 41,063 shares
@ $20.5, valued at
$841.8k
Sold 2,289 shares
@ $22, valued at
$50.4k
Sold 68,651 shares
@ $21.65, valued at
$1.5M
Exercised 41,063 options to buy
@ $9.12, valued at
$374.5k
Exercised 2,289 options to buy
@ $12.45, valued at
$28.5k
Exercised 68,651 options to buy
@ $9.58, valued at
$657.7k
|
|
| 06/11/2020 |
4
| Ros Matthew (Director) has filed a Form 4 on Unum Therapeutics Inc.|
Txns:
| Granted 14,331 options to buy
@ $0.63, valued at
$9k
|
|
| 04/08/2020 |
4
| Ros Matthew (Director) has filed a Form 4 on Unum Therapeutics Inc.|
Txns:
| Granted 49,887 options to buy
@ $0.3495, valued at
$17.4k
|
|
| 03/26/2020 |
4
| Ros Matthew (See Remarks) has filed a Form 4 on Epizyme, Inc.|
Txns:
| Granted 1,563 shares
@ $0
Sold 1,243 shares
@ $15.28, valued at
$19k
|
|
| 02/05/2020 |
4
| Ros Matthew (See Remarks) has filed a Form 4 on Epizyme, Inc.|
Txns:
| Granted 11,688 shares
@ $0
Granted 56,213 options to buy
@ $21.39, valued at
$1.2M
|
|
| 01/27/2020 |
4
| Ros Matthew (See Remarks) has filed a Form 4 on Epizyme, Inc.|
Txns:
| Granted 5,000 shares
@ $0
Sold 1,847 shares
@ $24.64, valued at
$45.5k
Paid exercise price by delivering 2,395 shares
@ $22.4, valued at
$53.6k
|
|
| 01/06/2020 |
4
| Ros Matthew (Director) has filed a Form 4 on Unum Therapeutics Inc.|
Txns:
| Granted 24,274 options to buy
@ $0.72, valued at
$17.5k
|
|
| 10/03/2019 |
4
| Ros Matthew (Director) has filed a Form 4 on Unum Therapeutics Inc.|
Txns:
| Granted 12,509 options to buy
@ $1.41, valued at
$17.6k
|
|
| 07/29/2019 |
4
| Ros Matthew (Director) has filed a Form 4 on Unum Therapeutics Inc.|
Txns:
| Granted 28,661 options to buy
@ $2.05, valued at
$58.8k
|
|
| 07/29/2019 |
3
| Ros Matthew (Director) has filed a Form 3 on Unum Therapeutics Inc. |
| 06/14/2019 |
4
| Ros Matthew (See Remarks) has filed a Form 4 on Epizyme, Inc.|
Txns:
| Granted 4,000 shares
@ $0
Sold 1,185 shares
@ $12.1, valued at
$14.3k
|
|
|
|
|